LeMaitre Vascular, Inc. Plans Quarterly Dividend of $0.25 (NASDAQ:LMAT)

LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced a quarterly dividend on Tuesday, August 4th. Investors of record on Thursday, August 20th will be given a dividend of 0.25 per share by the medical instruments supplier on Thursday, September 3rd. This represents a c) annualized dividend and a yield of 0.9%. The ex-dividend date is Thursday, August 20th.

LeMaitre Vascular has increased its dividend by an average of 0.2%per year over the last three years and has increased its dividend every year for the last 14 years. LeMaitre Vascular has a dividend payout ratio of 42.0% indicating that its dividend is sufficiently covered by earnings. Research analysts expect LeMaitre Vascular to earn $3.27 per share next year, which means the company should continue to be able to cover its $1.00 annual dividend with an expected future payout ratio of 30.6%.

LeMaitre Vascular Stock Up 2.1%

LMAT opened at $105.78 on Wednesday. The company has a fifty day moving average of $97.41 and a two-hundred day moving average of $100.04. The stock has a market capitalization of $2.42 billion, a price-to-earnings ratio of 39.03, a PEG ratio of 2.88 and a beta of 0.53. LeMaitre Vascular has a fifty-two week low of $79.39 and a fifty-two week high of $118.01. The company has a debt-to-equity ratio of 0.42, a quick ratio of 12.20 and a current ratio of 14.32.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 EPS for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07). The business had revenue of $70.38 million for the quarter, compared to analyst estimates of $71.47 million. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. LeMaitre Vascular’s revenue was up 9.6% on a year-over-year basis. During the same quarter last year, the business earned $0.60 earnings per share. On average, research analysts expect that LeMaitre Vascular will post 3 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Zacks Research cut shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Barrington Research lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Wells Fargo & Company boosted their price objective on LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a research note on Wednesday, May 6th. Citizens Jmp raised their target price on LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a research report on Wednesday, May 6th. Finally, Weiss Ratings cut LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, June 30th. Four research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $112.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.